Brazilian Authorities Greenlight BASF’s Biofungicide Serenade
LIMBURGERHOF, Germany, July 7th, 2011 – BASF announced that the biological fungicide Serenade was granted registration for apples, onions, and strawberries in the key agriculture market of Brazil.
http://www.basf.com/group/pressrelease/P-11-347

Breakthrough therapy PRADAXA® (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in Europe
4 August 2011 – This EU label extension means that millions of AF patients across Europe will have access to a new treatment for the prevention of AF-related strokes.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/04_aug_2011_dabigatranetexilate.html

Brief overview of changes in clinical trials and non-interventional studies resulting from a new Drug Law in Slovakia
A final version as passed by Parliament on 13th September 2011, signed by President on 7th October 2011 and published in the Slovak statute-book as Act 362/2011 Coll.
http://lv-cro.com/regulatory-news.htm

BTB Locutores
Locutores de anuncios comerciales y para empresas
http://personales.ya.com/locuciones/

BTG Acquires US Marketing Rights to Wellstat's Investigational Antidote for 5-FU Overexposure
6 July 2011 - BTG will have exclusive rights to market, sell and distribute uridine triacetate for this indication in the US for up to 10 years from marketing approval.
http://www.btgplc.com/page/15085/btg-acquires-us-marketing-rights-to-wellstat8217s-investigational-antidote-for-5-fu-overexposure

BTG plc: Annual General Meeting and Interim Management Statement
20 July 2011: The following summarises comments to be made by Dr John Brown, Chairman, and Louise Makin, CEO, at the Company’s AGM, which takes place at 10.30am today.
http://www.btgplc.com/page/15153/media/press-releases/2011/btg-plc-annual-general-meeting-and-interim-management-statement

BTG plc: FDA accepts Biologics License Application file for Voraxaze® (glucarpidase) and grants Priority Review
20 September 2011 - Glucarpidase is an experimental treatment for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function.
http://www.btgplc.com/page/15505/media/press-releases/2011/btg-plc-fda-accepts-biologics-license-application-file-for-voraxaze174-glucarpidase-and-grants-priority-review

BTG plc: Final Results
London, UK, 25 May 2011: BTG plc (LSE: BGC), the specialist healthcare company, today announces its final results for the year ended 31 March 2011
http://www.btgplc.com/page/14733/btg-plc-final-results

BTG plc: Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™) in Multiple Sclerosis Reported
11 July 2011: Louise Makin, BTG’s Chief Executive Officer, commented: “We’re delighted to see more positive news on one of our late-stage partnered development programmes.
http://www.btgplc.com/page/15106/btg-plc-top-line-results-from-first-phase-3-study-of-alemtuzumab-lemtrada8482-in-multiple-sclerosis-reported

BTG plc: ZYTIGA™ (abiraterone acetate) approved in the EU
7 September 2011: BTG will receive an undisclosed milestone payment following the EU approval together with a royalty on worldwide sales of abiraterone acetate.
http://www.btgplc.com/page/15431/media/press-releases/2011/btg-plc-zytiga8482-abiraterone-acetate-approved-in-the-eu

Anterior

5

6

7

8

9

10

11

12

13

Siguiente